CoChat

Improved survival in tumor-bearing SCID mice treated with interferon-γ-inducible protein 10 (IP-10/CXCL10)

Open access
Arenberg, Douglas, White, Eric, Burdick, Marie, Strom, Scott, Strieter, Robert · 2001 · Cancer Immunology Immunotherapy

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Tumor growth requires angiogenesis, which in turn requires an imbalance in the presence of angiogenic and angiostatic factors. We have shown that the CXC chemokine family, consisting of members that are either angiogenic or angiostatic, is a major determinant of tumor-derived angiogenesis in non-small-cell lung cancer (NSCLC). Intratumor injection of interferon-inducible protein 10 (IP-10, or CXCL10), an angiostatic CXC chemokine, led to reduced tumor growth in a SCID mouse model of NSCLC. In this study, we hypothesized that treatment with CXCL10 would, by restoring the angiostatic balance, improve long-term survival in NSCLC-bearing SCID mice. To test this hypothesis, A549 NSCLC cells were injected in the subcutis of the flank, followed by intratumor injections with CXCL10 continuously (group I), or for ten weeks (group II), or a control group (human serum albumin). Median survival was 169, 130, and 86 days respectively (P<0.0001). We extended these studies to examine the mechanism of prolonged survival in CXCL10-treated mice. CXCL10 treatment inhibited lung metastases, but was dependent upon continued treatment, and was associated with an increased rate of apoptosis in the primary tumor, with no direct effect on the proliferation of the NSCLC cells. Furthermore, the inhibition of lung metastases was due to the angiostatic effect of CXCL10 on the primary tumor, since the rate of apoptosis within lung metastases was unaffected. These data suggest that anti-angiogenic therapy of human lung cancer should be continued indefinitely to realize persistent benefit, and confirms the anti-metastatic capacity of localized angiostatic therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-001-0231-9

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 6

  1. American Cancer Society (2001) 2000 Cancer Facts and Fig- ures: Selected Cancers, Vol. 2000. American Cancer Society, Atlanta
  2. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Anti- angiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments]. Nature 390: 404
  3. Carney DN (1988) Cancers of the lungs. In: Fishman AP (ed) Pulmonary diseases and disorders. McGraw-Hill, New York, p 1885
  4. Folkman J (1993) Tumor angiogenesis. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weischelbaum RR (eds) Cancer Medicine, Vol. 1. Lea and Febiger, Philadelphia, p 153
  5. Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression [see comments]. Nat Med 1: 149
  6. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo [In Process Citation]. J Immunol 164: 4558

Cited by

Metadata

Authors
Arenberg, D., White, E., Burdick, M., Strom, S., & Strieter, R.
Affiliations
  • University of Michigan (US)
  • University of California, Los Angeles (US)
Corresponding author
Arenberg, Douglas
Venue
Cancer Immunology Immunotherapy
Published
2001-12-01
Volume
50
Issue
10
Pages
533-538
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2027099531
Cited by
73
References
12
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 6 · 2021: 10 · 2020: 8 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 2
FWCI
1.18
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
Funders
  • National Institutes of Health (5k08ca072543-05, CA72543, P50HL67665)
  • National Heart, Lung, and Blood Institute (HL66027, P50-HL-67665, P50HL067665, R01HL066027)
  • National Cancer Institute (CA-87879, R01CA087879, CA72543)
Topics
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords
CXCL10, non-small cell lung cancer, tumor angiogenesis, anti-angiogenic therapy, lung metastasis, tumor cell apoptosis, intratumoral injection, long-term survival, A549 cells, SCID mice
MeSH terms
Animals, Carcinoma, Non-Small-Cell Lung, Female, Humans, Interferon-gamma, Lung Neoplasms, Neovascularization, Pathologic, Tumor Cells, Cultured, Survival Analysis, Mice, SCID, Chemokines, CXC, Mice, Chemokine CXCL10

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.